CCXI:NSD-ChemoCentryx, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 55.81

Change

0.00 (0.00)%

Market Cap

USD 3.86B

Volume

0.20M

Average Target Price

USD 76.88 (+37.74%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.

Company Website : http://www.chemocentryx.com

Address : 850 Maude Avenue, Mountain View, CA, United States, 94043

Employees : 82

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.76

52 Week High : 65.43

Short Ratio : 7.87

52 Week Low : 27.47

Shorted Shares : 5,040,430

200 Day Moving Average : 55.70

Shorted Shares Previous Month : 5,237,908

50 Day Moving Average : 55.55

Shares Held By Insiders : 237.64%

Short Percentage : 7.00%

Shares Held by Institutions : 81.78%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD58.95B 22.22 16.42
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD54.85B 18.84 14.36
MRNA Moderna, Inc

N/A

 USD50.27B N/A N/A
SGEN Seagen Inc

N/A

 USD30.27B 63.87 62.62
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD27.10B 28.74 26.73
RPRX Royalty Pharma plc

N/A

 USD26.01B 22.60 9.61
BNTX BioNTech SE

N/A

 USD25.27B -99,999.99 N/A
BGNE BeiGene, Ltd

N/A

 USD25.02B N/A N/A
GMAB Genmab A/S

N/A

 USD23.59B 26.59 2.65
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing CCXI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 41.11% 68% D+ 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.11% 68% D+ 78% C+
Trailing 12 Months  
Capital Gain 84.01% 76% C 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 84.01% 76% C 86% B
Trailing 5 Years  
Capital Gain 639.21% 94% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 639.21% 94% A 96% A
Average Annual (5 Year Horizon)  
Capital Gain 111.39% N/A N/A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 111.39% N/A N/A 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 173.03% N/A N/A 5% F
Risk Adjusted Return 64.37% N/A N/A 80% B-
Market Capitalization 3.86B 90% A- 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 39.70 23% F 27% F
Price/Book Ratio 9.58 17% F 13% F
Price / Cash Flow Ratio -55.08 93% A 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -17.57% 88% B+ 36% F
Return on Invested Capital -97.00% 27% F 9% F
Return on Assets -7.00% 89% B+ 29% F
Debt to Equity Ratio 29.98% 40% F 56% F
Technical Ratios  
Short Ratio 7.87 32% F 18% F
Short Percent 10.79% 30% F 20% F
Beta 1.76 36% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.